Jasmina Fornbacher, APRN
Adult Health · Las Vegas, NVNPI 1164901245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 719 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 719 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$922
- Lilly USA, LLC$893
- GSK$885
- plus $6K from 33 others
What the payments were for
- Consulting fees$8006%
- Food & beverage$13,11394%
- Education$570%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- Creon$123
- Kerendia$104
- BREZTRI$100
How this compares
$13,970 in reported general payments places this provider in the 95th percentile of 90 adult health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 40 | $46,158 |
| OzempicSemaglutide | 25 | $41,786 |
| DapagliflozinDapagliflozin Propanediol | 21 | $26,783 |
| MounjaroTirzepatide | 17 | $26,783 |
| JardianceEmpagliflozin | 14 | $14,945 |
| TrulicityDulaglutide | 15 | $14,091 |
| EliquisApixaban | 12 | $8,860 |
| Rosuvastatin Calcium | 62 | $1,503 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,142 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $958 |
| Losartan Potassium | 106 | $892 |
| Atorvastatin Calcium | 137 | $813 |
| Levothyroxine Sodium | 90 | $746 |
| Metoprolol Succinate | 61 | $723 |
| Ezetimibe | 41 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,747 | $46,15840 claims |
| Novo NordiskOzempic | $1,752 | $41,78625 claims |
| Lilly USA, LLCMounjaro, Trulicity | $893 | $40,87432 claims |
| Boehringer IngelheimJardiance | $449 | $14,94514 claims |
| PfizerEliquis | $533 | $8,86012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 adult health providers in Nevada.
Other adult health in Las Vegas
- Marcia Castro-RosenbergLas Vegas$64K
- Amanda SquiersLas Vegas$36K
- Marcella PomeranzLas Vegas$14K
- Karisa SonLas Vegas$10K
- Jessica LuceroLas Vegas$6K
- Monica LynamLas Vegas$5K
- Thomas McNeilLas Vegas$5K
- Roger ConantLas Vegas$4K
- Ruth RamirezLas Vegas$4K
- Gener CruzLas Vegas$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.